MCRB Stock: Seres Therapeutics, Inc. Stock Price, Analysis & Insights
Get live mcrb stock price $20.01, comprehensive Seres Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time mcrb stock data and investment insights.
Loading chart...
Company Overview
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Company Information
- CEO
- Thomas J. DesRosier
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 103
Contact Information
- Address
- 200 Sidney Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 22.7)
✓ Lower volatility stock (Beta: 0.20) may provide portfolio stability
Business Model & Strategy
Seres Therapeutics, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Thomas J. DesRosier, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Seres Therapeutics, Inc. competes in the Biotechnology within the broader Healthcare. With 175.6 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Select, Seres Therapeutics, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Seres Therapeutics, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Seres Therapeutics, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Seres Therapeutics, Inc.
- ⚠Investors should consider how Seres Therapeutics, Inc. fits within their overall portfolio allocation
Market Cap
175.62M
P/E Ratio
22.74
Beta
0.20
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 175.62M market capitalization
- Trading Volume: 93.49K shares traded today
- Price Range: 52-week range of $6.53 - $24.66
- Exchange: Listed on NASDAQ Global Select
Financial Metrics
Market Analysis for Seres Therapeutics, Inc.
Seres Therapeutics, Inc. (MCRB) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 175.62M, the company represents a significant player in its market. The stock is currently trading at $20.01 with a negativedaily change of 7.52%.
The company's 103 employee base and presence on the NASDAQ Global Selectexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 22.74, beta of 0.20, and 52-week price range from $6.53 to $24.66when evaluating investment opportunities.
Why Invest in Seres Therapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Select)
- • Experienced leadership under Thomas J. DesRosier
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.